MHBP Overview webinar The MHBP Plan options and benefits webinar is an overview of all three MHBP plans, rates and benefits
Srivastava MD, Srivastava BI, Brouhard B
Current marketed formulations Semaglutide (Rybelsus, Ozempic, and Wegovy) Oral drug delivery offers significant advantages in terms of patient adherence, particularly in the chronic management of T2DM
In addition, the rate of hypoglycemia in patients taking vildagliptin is similar to that of patients taking placebo
Supports healthy digestion and regularity*
Shoemaker quote IMCIVREE packaging IMCIVREE 3D Render -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m